These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1058 related articles for article (PubMed ID: 8974438)

  • 1. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vascular manifestations in systemic sclerosis (scleroderma)].
    Cafagna D; Melon F; Balbi M; Ponte E
    Minerva Med; 1998 May; 89(5):153-61. PubMed ID: 9676180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin and Raynaud's phenomenon.
    Seibold JR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S95-8. PubMed ID: 2412070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis.
    Sunderkötter C; Riemekasten G
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii33-5. PubMed ID: 16987831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autonomic nervous system dysfunction in sclerodermic and primary Raynaud's phenomenon.
    Pancera P; Sansone S; Presciuttini B; Montagna L; Cerù S; Lunardi C; Lechi A
    Clin Sci (Lond); 1999 Jan; 96(1):49-57. PubMed ID: 9857106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raynaud's phenomenon: pathogenesis and management.
    Bakst R; Merola JF; Franks AG; Sanchez M
    J Am Acad Dermatol; 2008 Oct; 59(4):633-53. PubMed ID: 18656283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the diagnosis and management of scleroderma-related vascular complications.
    Kerin K; Yost JH
    Compr Ther; 1998; 24(11-12):574-81. PubMed ID: 9847974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma beta-thromboglobulin in the differential diagnosis of Raynaud's phenomenon.
    Seibold JR; Harris JN
    J Rheumatol; 1985 Feb; 12(1):99-103. PubMed ID: 2580093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Calcium antagonists and Raynaud's phenomenon].
    Hachulla E; Devulder B
    Therapie; 1993; 48 Spec No():707-11. PubMed ID: 8091357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serial computed thermography for Raynaud's phenomenon of patient with progressive systemic sclerosis (PSS)].
    Tomono N; Kuriyama T; Mori M; Takahashi Y; Mitsuda T; Aihara Y; Yokota S
    Ryumachi; 1996 Jun; 36(3):522-7. PubMed ID: 8779789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenesis of Raynaud's phenomenon, disease and syndrome].
    Bartolo M; Antignami PL; Cestari M; Rufini E
    Angiologia; 1985; 37(4):161-70. PubMed ID: 4025912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 53.